[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627670":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":59,"collaborators":22,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":22,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":22,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":47,"whyStopped":22,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Hospital Universitario Dr. Jose E. Gonzalez","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Epcoritamab + GemOx","EXPERIMENTAL","Subjects will receive Gemcitabine\u002FOxaliplatin at usual doses as well as Epcoritamab with 2 step up doses followed by 12 mg weekly for 3 cycles.",[13,14,15],"Drug: Epcoritamab","Drug: Gemcitabine (1000 mg\u002Fm2)","Drug: Oxaliplatin",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Epcoritamab","Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Gemcitabine (1000 mg\u002Fm2)","Subjects will receive gemcitabine 1000 mg\u002Fm2 on days 1 and 15 of the three 21-day cycles.",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Oxaliplatin","Subjects will receive oxaliplatin 100 mg\u002Fm2 on day 1 of three 21-day cycles.",[9],[32],{"name":33,"affiliation":34,"role":35},"Perla R Colunga-Pedraza, MD","Hospital Universitario \"Dr. José Eleuterio González\"","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},"CONTACT","+52 8110761973","alrep_rcp@gmail.com",{"name":42,"role":38,"phone":43,"phoneExt":22,"email":44},"Natalia Huergo-Treviño, MD","+524442416594","nat.hue94@gmail.com",[46],{"facility":34,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":22},"RECRUITING","Monterrey","Nuevo León","64640","Mexico","MX",{"type":54,"coordinates":55},"Point",[56,57],-100.31721,25.68435,{"lat":57,"lon":56},{"type":35,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Perla Rocío Colunga Pedraza","Associated professor","100627670","phase-2-low-dose-epcoritamab-plus-gemox-in-rr-dlbcl-100627670",false,"NCT07451652","Low Dose Epcoritamab Plus GemOx in R\u002FR DLBCL","Low Dose Epcoritamab Plus Gemcitabine\u002FOxaliplatin in Treatment of Transplant Eligible Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Inclusion Criteria:\n\n* Subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant\n* ECOG 0-2\n* Women of reproductive age who agree on getting a contraceptive method\n* Subjects who fulfill Lugano´s criteria for disease activity\n* Subjects who voluntarily accept to participate in this study\n\nExclusion Criteria:\n\n* Active bacterial, viral or fungal infection\n* Subjects who have already received an autologous o allogeneic stem cell transplantation\n* Subjects with other active neoplasias\n* Subjects with end-stage failure","ALL","18 Years","65 Years",{"count":73,"type":74},10,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","In this study, researchers are looking to determine whether Gemcitabine\u002FOxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed\u002Frefractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.",[80],"Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[82,83,84,85,86,87],"relapsed\u002Frefractory diffuse large B cell lymphoma","epcoritamab","GemOx","gemcitabine","oxaliplatin","autologous stem cell transplant","2026-03-26",{"date":90,"type":91},"2026-04-01","ACTUAL",{"date":93,"type":91},"2026-03-17",{"date":95,"type":74},"2027-09",{"name":5,"class":6},1]